Market Cap
$5.6B
MIRM
Mirum Pharmaceuticals, Inc.
$82.25 ▼ -1.99%
Prev close $83.92Market cap$5.6B
ConsensusStrong Buy
12-mo target$145.79 (+77.2%)
▲ Bullish
Analyst conviction 10/10
Insider Selling Cluster (2 insiders)High Impact Filing (8/10)31 New Institutional Positions19 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MIRM right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (95%)
Inst. Holders
50 funds
Inst. Value
$5.2B
Inst. Activity
31 buys / 19 sells
Insider Activity
$0.00 buy / $17.1M sell
Insider Net $
-$17.1M
Social Sentiment
50° Neutral
SEC Reports
16
Price chart 30d -17.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 short_volume
Short Volume: MIRM — 63.1% short (0.4M / 0.6M)
Short: 395,217 | Exempt: 9,519 | TRF Vol: 626,305 | Short Ratio: 63.1% | Off-exchange volume (dark p
Sep 14, 2026 Insider
BJERKHOLT ERIC sold 9,943 shares
CHIEF FINANCIAL OFFICER @ $98.37 ($978.1K)
Sep 11, 2026 Insider
BJERKHOLT ERIC acquired via exercise 18,333 shares
CHIEF FINANCIAL OFFICER
Sep 2, 2026 Insider
Aug 20, 2026 SEC Howe Jolanda sold 658 shares
SVP, GLOBAL CONTROLLER @ $100.00 ($65.8K)
Two insiders at Mirum Pharmaceuticals sold a combined $4.60M in shares over a one-week window. SVP/Global Controller Jol
CLUSTER — Impact 3/10
Mirum Pharmaceuticals CEO Christopher Peetz and CFO Eric Bjerkholt sold a combined $1.75M in open-market stock within tw
CLUSTER — Impact 3/10
CEO Christopher Peetz executed a cluster of open-market sales totaling ~$1.98M, including a single-day sale of 11,683 sh
CLUSTER — Impact 5/10
Jun 30, 2026 Inst.
FMR LLC — ADD
3,670,314 shares ($429.7M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
95% rate it Buy or better · 20 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| Sep 29, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Sep 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Aug 27, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Aug 6, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 6, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Aug 6, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Aug 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 7, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 2, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Aug 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Jul 1, 2026 | 8 | 11 | 1 | 0 | 0 | 95% | |
| Jun 1, 2026 | 7 | 11 | 1 | 0 | 0 | 95% | |
| May 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 10 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Price targets
Where 14 covering analysts think MIRM trades over the next 12 months.
$145.79 +77.2% upside Strong Buy
Current$82.25 Low$118.00 Median$138.50 High$195.00 14 analysts
$118.00$195.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 4 bullish, 1 bearish, 2 mixed, 9 neutral · avg impact 4.3/10.
NEUTRALCLUSTER3/10
Two insiders at Mirum Pharmaceuticals sold a combined $4.60M in shares over a one-week window. SVP/G
Aug 20, 2026
NEUTRALCLUSTER3/10
Mirum Pharmaceuticals CEO Christopher Peetz and CFO Eric Bjerkholt sold a combined $1.75M in open-ma
Aug 13, 2026
BEARISHCLUSTER5/10
CEO Christopher Peetz executed a cluster of open-market sales totaling ~$1.98M, including a single-d
Aug 11, 2026
NEUTRAL1443/10
Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of inte
Aug 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
short_volume
Short Volume: MIRM — 63.1% short (0.4M / 0.6M)
Short: 395,217 | Exempt: 9,519 | TRF Vol: 626,305 | Short Ratio: 63.1% | Off-exchange volume (dark pool + OTC)
Sep 26, 2026
fda_pdufa
PDUFA: MIRM — zilurgisertib in Fibrodysplasia Ossificans Progressiva — 2026-09-26
FDA target action date 2026-09-26 for MIRM (Mirum Pharmaceuticals, Inc.). Drug: zilurgisertib. Indication: Fibrodysplasia Ossificans Progressiva. FDA
Sep 9, 2026
ftd
FTD: MIRM — 17,137 shares ($1.7M) failed to deliver
Settlement: 20260909, Price: $99.53, FTD Value: $1,705,645.61, MIRUM PHARMACEUTICALS INC COM
Aug 6, 2026
short_volume
Short Volume: MIRM — 66.9% short (0.9M / 1.4M)
Short: 949,968 | Exempt: 51,894 | TRF Vol: 1,419,521 | Short Ratio: 66.9% | Off-exchange volume (dark pool + OTC)
Aug 5, 2026
earnings_calendar
MIRM Q2 2026 Earnings After Market Close — 2026-08-05
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.42 | $-0.53–$-0.32 | -950.0% | +38.0% | — | $0.2B | 2 |
| Next Q | $-0.61 | $-0.88–$-0.34 | -408.3% | -33.3% | 1↑ 0↓ | $0.2B | 2 |
| Current FY | $-15.14 | $-15.14–$-15.14 | -3121.3% | -6.3% | — | $0.7B | 1 |
| Next FY | $-0.35 | $-1.24–$0.40 | 97.7% | -84.4% | 0↑ 1↓ | $0.8B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.425 | — |
| 7d ago | $-0.686 | +0.261 |
| 30d ago | $-0.686 | +0.261 |
| 60d ago | $-0.703 | +0.278 |
| 90d ago | $-0.703 | +0.278 |
Institutional ownership
Which big funds own MIRM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $5.2B total value (44,405,229 shares) as of 2026-Q2. Top holders: NOMURA, Jupiter, BlackRock,. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| Jupiter Topco LLC | 5,909,184 | $691.7M | 13.3% | — |
| BlackRock, Inc. | 4,390,063 | $513.9M | 9.9% | — |
| FMR LLC | 3,670,314 | $429.7M | 8.3% | ADD +86.7% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,377,019 | $278.3M | 5.4% | ADD +66.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,254,109 | $263.9M | 5.1% | — |
| STATE STREET CORP | 2,170,689 | $254.1M | 4.9% | — |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1,404,741 | $164.5M | 3.2% | DOUBLED +318.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 1,393,908 | $163.2M | 3.1% | — |
| Invesco Ltd. | 1,364,084 | $159.7M | 3.1% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | ADD | 1,965,375 | 3,670,314 | +86.7% | $429.7M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 1,432,083 | 2,377,019 | +66.0% | $278.3M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | DOUBLED | 335,669 | 1,404,741 | +318.5% | $164.5M |
| Capital World Investors | ADD | 724,415 | 1,153,480 | +59.2% | $135.0M |
| Polar Capital Holdings Plc | DOUBLED | 283,484 | 845,524 | +198.3% | $99.0M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | ADD | 405,321 | 752,044 | +85.5% | $88.0M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 219,255 | 726,694 | +231.4% | $85.1M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 911,419 | 606,427 | -33.5% | $71.0M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | 286,406 | 384,570 | +34.3% | $45.0M |
| MORGAN STANLEY | TRIM | 524,566 | 351,404 | -33.0% | $41.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$17.1M — $0.00 bought, $17.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | SELL | 9,943 | $98.37 | $978.1K |
| Sep 11, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | EXERCISE | 18,333 | — | — |
| Sep 2, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 658 | $100.00 | $65.8K |
| Sep 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 21,688 | $98.91 | $2.1M |
| Sep 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | EXERCISE | 30,000 | $2.94 | $88.1K |
| Sep 1, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | SELL | 8,312 | $98.08 | $815.2K |
| Aug 18, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | EXERCISE | 40,000 | $6.27 | $250.8K |
| Aug 18, 2026 | Howe Jolanda | SVP, GLOBAL CONTROLLER | SELL | 40,000 | $100.00 | $4.0M |
| Aug 11, 2026 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | SELL | 6,001 | $99.90 | $599.5K |
| Aug 10, 2026 | Peetz Christopher | CHIEF EXECUTIVE OFFICER | EXERCISE | 20,000 | $2.94 | $58.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MIRM.
Shares short
6,281,413
Settlement Sep 15, 2026
Change vs prior
+1.8%
Semi-monthly cycle
Days to cover
12.0
At avg daily volume
Of shares outstanding
≈9.7%
Estimate — not % of float
All MIRM filing & press-release reports (16)
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 13, 2026
- CLUSTER reportAug 11, 2026
- 144 reportAug 11, 2026
- 8-K reportAug 6, 2026
- CLUSTER reportJul 9, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 10, 2026
- CLUSTER reportJun 2, 2026
- 144 reportJun 1, 2026
- 144 reportJun 1, 2026
- 8-K reportMay 18, 2026
- 8-K reportMay 4, 2026
- 8-K reportApr 27, 2026
- 144 reportApr 15, 2026
- 8-K reportFeb 25, 2026